Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Renerve Limited ( (AU:RNV) ) has shared an update.
ReNerve Limited has issued 1,010,101 fully paid ordinary shares at $0.099 per share, using a placement that did not require a prospectus under Australian corporations law. The company confirmed it remains compliant with its financial reporting and continuous disclosure obligations and that there is no excluded information that would need to be disclosed, signalling regulatory compliance and transparency around the new capital issuance.
More about Renerve Limited
ReNerve Limited is an Australian medical device company focused on transforming nerve repair through breakthrough technology for peripheral nerve injuries. Founded by a neurosurgeon and medtech researchers, it has developed scientifically backed, ready-to-use solutions such as the FDA-cleared NervAlign Nerve Cuff, which is improving surgical outcomes and reducing post-operative pain for patients worldwide.
Average Trading Volume: 332,074
Technical Sentiment Signal: Sell
See more insights into RNV stock on TipRanks’ Stock Analysis page.